DUBLIN–(BUSINESS WIRE)–The “Achondroplasia – Pipeline Review, H2 2020” drug pipelines has been added to ResearchAndMarkets.com’s offering.
Achondroplasia – Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Achondroplasia (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Achondroplasia (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Achondroplasia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 2, 1 and 1 respectively.
Achondroplasia (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Achondroplasia (Musculoskeletal Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Achondroplasia (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Topics Covered:
Introduction
- Report Coverage
Achondroplasia – Overview
Achondroplasia – Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
Achondroplasia – Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
Achondroplasia – Companies Involved in Therapeutics Development
- Ascendis Pharma A/S
- BioMarin Pharmaceutical Inc
- Pfizer Inc
- PhaseBio Pharmaceuticals Inc
- QED Therapeutics Inc
- Ribomic Inc
- TagCyx Biotechnologies
Achondroplasia – Drug Profiles
ACP-015 – Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
Aptamer for Achondroplasia – Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
Fusion Protein to Agonize NPR2 for Achondroplasia – Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
infigratinib phosphate – Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
RBM-007 – Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
TA-46 – Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
vosoritide – Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
Achondroplasia – Dormant Projects
Achondroplasia – Product Development Milestones
- Featured News & Press Releases
- Sep 11, 2020: BioMarin announces presentation of Vosoritide phase 3 data in children with Achondroplasia at the American Society for Bone and Mineral Research 2020 Annual Meeting
- Sep 08, 2020: BioMarin announces The Lancet publishes detailed vosoritide phase 3 data demonstrating statistically significant increase in annualized growth velocity (AGV) over 52 weeks in children with achondroplasia
- Aug 20, 2020: BioMarin submits new drug application to U.S. Food and Drug Administration for Vosoritide to treat children with achondroplasia
- Aug 13, 2020: European Medicines Agency validates BioMarin’s Marketing Authorization Application for vosoritide to treat children with achondroplasia
- Aug 12, 2020: Ascendis Pharma receives Orphan Designation for TransCon CNP for the treatment of achondroplasia in Europe
- Jul 23, 2020: BioMarin submits marketing authorization application to European Medicines Agency for vosoritide to treat children with achondroplasia
- Jul 15, 2020: BridgeBio Pharma’s QED Therapeutics doses first child in Phase 2 clinical trial of the investigational medicine Infigratinib in Achondroplasia
- Jul 15, 2020: RIBOMIC announces dosing of first subject in RBM-007 phase 1 clinical trial for Achondroplasia
- May 11, 2020: BridgeBio Pharma’s QED Therapeutics announces preclinical data demonstrating potential of low-dose infigratinib in achondroplasia
- Apr 06, 2020: BioMarin plans regulatory submissions for marketing authorization of Vosoritide to treat children with achondroplasia in 3Q 2020 in both US and Europe
- Jan 08, 2020: Wacker Biotech provides active ingredient to treat achondroplasia in children for Ascendis Pharma global phase-2 trial
- Dec 16, 2019: BioMarin announces positive final results from placebo-controlled phase 3 data in children with achondroplasia treated with Vosoritide
- Nov 14, 2019: BioMarin announces cumulative additional height gain of 9.0 cm over 54 months versus natural history in children with Achondroplasia treated with Vosoritide in phase 2 study
- Nov 06, 2019: BioMarin to highlight innovative development pipeline including vosoritide at R&D Day on November 14th
- Oct 17, 2019: QED and parent company BridgeBio announce preclinical data supporting tolerability and activity of low-dose infigratinib in treating Achondroplasia
Appendix
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/le7m6q
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900